Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Panel Narrowly Votes Against Cough/Cold Drugs For Children Up To Age 6

This article was originally published in The Tan Sheet

Executive Summary

An FDA advisory panel decided in split votes Oct. 19 to recommend immediately that all OTC cough/cold medicines should not be used for 2-to 5-year-old children but are safe for 6- to 12-year-olds

Related Content

Incoming CHPA Head Melville Brings Pharma Resume To OTC Learning Curve
Health Canada Recommends Children Under 6 Not Use OTC Cold Products
FDA readies for cough/cold meeting
FDA Call For Pediatric Cough/Cold Input Signals New Rule Is A Long Way Off
Tailored Dosing Devices Could Improve Compliance, FDA's Levy Says
U.K. Pulls Plug On Some Cough/Cold Products For Children Under 2
Removing Pediatric OTC Cold Drugs Would Create New Problems – CHPA
Waxman Bill Would Alter OTC Ad Rules, Streamline FDA Monograph Authority
Perrigo Says PSE Sales Up Again, Business From Leiner Helps Drive Growth
CHPA Rolls Out Pediatric Cough/Cold Education Campaign





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts